Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.97 |
| ▸ | MAPT | P10636 | 6/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.97 |
| ▸ | HPGD | P15428 | 1/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
| ▸ | FNTA | P49354 | 1/20 | 0.74 |
| ▸ | FNTB | P49356 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | APAF1 | O14727 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MPO | P05164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27763159 | 0.98 | MEN1 (1.00) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL29362070 | 0.98 | MEN1 (1.00) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL125249 | 0.98 | MEN1 (1.00) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL9494228 | 0.97 | MEN1 (0.97) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL18582291 | 0.97 | MEN1 (0.97) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| Lactic Acid SCHEMBL27789008 | 0.88 | MAPT (0.81) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL4620881 | 0.88 | MAPT (0.81) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| Kurasoin B SCHEMBL29489947 | 0.85 | SLC6A2 (1.00) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| Dl-Tryptophan SCHEMBL2174790 | 0.85 | KDM4E (0.82) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| D-Tryptophan SCHEMBL2176030 | 0.85 | KDM4E (0.82) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501503-B1 | SUBSTANTIALLY PURE SOLID FORM OF THE ENOL TAUTOMER OF 3-INDOLYPYRUVIC ACID FOR USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISTURBANCES | POLIFARMA SPA (IT) | 2008-12-24 | — | — | EP | disclosed |
| US-20050208125-A1 | Substantially pure solid form of the enol tautomer of 3-indolypyruvic acid for use in the treatmetn of central nervous system disturbances | POLIFARMA S.P.A. (IT) | 2005-09-22 | — | — | US | disclosed |
| EP-1501503-A1 | SUBSTANTIALLY PURE SOLID FORM OF THE ENOL TAUTOMER OF 3-INDOLYPYRUVIC ACID FOR USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISTURBANCES | POLIFARMA S.p.A. (IT) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003094914-A1 | SUBSTANTIALLY PURE SOLID FORM OF THE ENOL TAUTOMER OF 3-INDOLYLPYRUVIC ACID FOR USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISTURBANCES | POLIFARMA S.P.A. (IT) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050208125-A1 | Substantially pure solid form of the enol tautomer of 3-indolypyruvic acid for use in the treatmetn of central nervous system disturbances | NLN, PYGB, MAPT | MEN1 1207/4885KMT2A 2020/4885MAPT 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.